Table 2.
Results of the in vitro assays of the chosen compounds with possible anti-T. cruzi activity.
| Compound | IC50 (µM) a | LC50 (µM) b | SI c |
|---|---|---|---|
| UBMC-6 | 14.25 ± 1 | 34.11 ± 3.14 | 2.39 |
| UBMC-8 | 18.26 ± 1.30 | 55.2 ± 2.25 | 3.02 |
| UBMC-7 | 19.44 ± 0.35 | 62.3 ± 5.63 | 3.2 |
| UBMC-1 | 34.92 ± 3.87 | 61.66 ± 456 | 1.76 |
| UBMC-3 | 37.53 ± 2.65 | 197.9 ± 7.84 | 5.27 |
| UBMC-2 | 62.44 ± 4.62 | 44.5 ± 2.88 | 0.71 |
| UBMC-5 | 69.82 ± 9.23 | 43.25 ± 7.53 | 0.61 |
| UBMC-4 | 72.13 ± 8.58 | 70.88 ± 6.33 | 0.98 |
| Benznidazole | 16.61 ± 4 | >200 (µg/mL) | 12.04 |
| Doxorrubicin | NA d | 3.91 ± 0.40 | NC e |
a IC50 inhibitory concentration of T. cruzi amastigote; b LC50 lethal concentration on human monocyte-derived macrophages (hMDMD); c SI selectivity index between hMDMD and amastigote; d NA not applicable; e NC not calculated. Data represent the mean value ± standard deviation